Drug intelligence / Profile preview

naproxen + peginterferon beta-1a

Development stage
Phase 3
Lead developer
Biogen
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration
Oral, Subcutaneous
01

Overview

This is a combination of two drugs, naproxen and peginterferon beta-1a. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever. Peginterferon beta-1a is a pegylated form of interferon beta-1a, an immunomodulatory agent used as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Peginterferon beta-1a binds to type I interferon receptors on cell surfaces, leading to regulation of gene expression that upregulates anti-inflammatory cytokines and downregulates pro-inflammatory cytokines; it also inhibits migration of activated T cells across the blood–brain barrier. The combination may be used adjunctively in MS patients to manage flu-like symptoms associated with interferon therapy or as part of clinical studies evaluating their combined effects.

02

Targets

IFNAR1 (Interferon alpha/beta receptor 1)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on naproxen + peginterferon beta-1a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naproxen + peginterferon beta-1a.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call